Investment Thesis

Strong — all assumptions holding Maintaining — minor concerns, thesis intact Weak — key assumptions under pressure Broken — critical assumption invalidated
Status STRONG
Conviction 77 / 100
Time Horizon 3-5 years
Over a 3-5 year horizon, BSE Ltd. will achieve sustained revenue growth and market share gains in non-derivatives segments, driven by the financialization of savings, increasing retail investor participation, and successful diversification into mutual fund distribution and SME listings, while maintaining its strong financial profile.

Conviction History

Assumptions

Holding — assumption intact At Risk — evidence weakening Broken — assumption invalidated Critical — if broken, thesis fails
#1 CRITICAL HOLDING 100

BSE Star MF transaction volumes will grow at a compound annual growth rate (CAGR) of over 20% and SME listings will increase by at least 25% annually through FY2028, driven by financialization trends and supportive SEBI policies.

GROWTH 70% VOLUME 30%
#2 HOLDING 70

BSE's average daily trading volume in the cash equity segment will grow at a CAGR of at least 15% through FY2028, outperforming general market growth and capturing increased retail participation.

VOLUME 70% PRICING 30%
#3 CRITICAL HOLDING 70

BSE will maintain a debt-free balance sheet throughout the forecast period, with total debt remaining at 0x EBITDA.

DEBT 100%
#4 HOLDING 77

BSE will maintain consolidated operating profit margins above 58% through FY2028, supported by stable technology infrastructure costs and pricing power in data dissemination and listing services.

COGS 40% PRICING 60%
#5 HOLDING 70

Annual capital expenditure will range between INR 150-200 crore, primarily directed towards technology upgrades and platform development to support growth initiatives and maintain competitive infrastructure.

CAPEX 100%
#6 CRITICAL HOLDING 70

No material regulatory sanctions or governance failures will occur that lead to significant operational disruption or reputational damage, beyond minor procedural lapses noted regarding remuneration disclosures.

GOING_CONCERN 100%

Recent Developments

Structural Tactical
GROWTH TACTICAL Feb 21, 2026

Sebi approves 4 IPOs including Integris Medtech, Alpine Texworld and Anjali Labtech

SEBI approved four new IPOs, including Integris Medtech (Rs 925 crore) and Alpine Texworld, to list on the BSE, strengthening the primary market pipeline.

GROWTH TACTICAL Feb 20, 2026

Kwality Wall's shares list with 26% discount at ₹29.80 apiece versus adjusted price of ₹40.20 on NSE - Mint

RBI tightened capital market exposure norms requiring bank guarantees to be backed by 50% collateral and banning bank funding for proprietary trading effective April 2026.

VOLUME STRUCTURAL Feb 17, 2026

BSE, Angel One shares fall up to 10% after RBI tightens capital market exposure norms

RBI tightened capital market exposure norms effective April 2026, requiring bank guarantees to exchanges be backed by 50% collateral and banning bank funding for proprietary trading.

VOLUME STRUCTURAL Feb 15, 2026

IPO Calendar: Gaudium IVF to open next week as Fractal, Aye Finance head for listing

BSE Q3 FY26 PAT surged 174% to Rs 602 crore, driven by record equity derivatives volume and 87.4% market share in mutual fund transactions.

VOLUME STRUCTURAL Feb 14, 2026

BSE gets Sebi nod to launch 'Focused Midcap Index' futures and options contracts

SEBI approved BSE to launch 'Focused Midcap Index' derivatives; HUL demerger of Kwality Wall's (2.3B shares) confirmed for listing on Feb 16.

GROWTH STRUCTURAL Feb 10, 2026

BSE Q3 Results: Cons PAT skyrockets 174% YoY to Rs 602 crore, revenue soars 62%

Q3 FY26 PAT surged 174% YoY to Rs 602 crore, driven by an 86% increase in transaction revenue from derivatives scaling.

VOLUME TACTICAL Feb 09, 2026

IPO Calendar This Week: Aye Finance, Fractal Analytics among major issues - Full list - ET Now

BSE to list Aye Finance (Rs 1,010 cr) and Marushika Technology, signaling robust IPO volume and SME segment momentum.

Investor Documents